Important Announcements

Nondiscrimination Statement Update

Boston Medical Center Health System complies with applicable Federal civil rights laws and does not discriminate on the basis of age, race, color, national origin (including limited English proficiency and primary language), religion, culture, physical or mental disabilities, socioeconomic status, sex, sexual orientation and gender identity and/or expression. BMCHS provides free aids and services to people with disabilities and free language services to people whose primary language is not English.

To see our full nondiscrimination statement, click here.

Campus Construction Update

Starting September 14, we’re closing the Menino building lobby entrance. This, along with the ongoing Yawkey building entrance closure, will help us bring you an even better campus experience that matches the exceptional care you've come to expect. Please enter the Menino and Yawkey buildings through the Moakley building, and make sure to leave extra time to get to your appointment. Thank you for your patience. 

Click here to learn more about our campus redesign. 

Clinical Data

Select your language:

All Biorepository samples are paired with a minimal amount of clinical data. All samples and data are coded at the time of release to the investigator. It is the responsibility of the investigator to obtain IRB approval for the data they are requesting and obtaining from the Biorepository and/or the CDW. The Biorepository team will request documentation of IRB approval before any data are released.

Prospective cohort samples

All cohort participants are administered a questionnaire. The questionnaire covers COVID risk factors (e.g., travel, essential work, exposures), signs and symptoms, medical and social history, and substance use. Additionally, a variety of clinical variables are abstracted from the electronic medical record (EMR) for all cohort participants.

REDCap questionnaire data dictionary (Excel Doc)

Questionnaire data dictionary 

EMR data dictionaries:

Before submitting a request for prospective cohort samples, investigators are encouraged to consult with the Biorepository team to discuss if the available data will meet their needs. If an investigator requires data beyond the standard variables provided above, it is their responsibility to obtain it (e.g., consult with the Clinical Data Warehouse [CDW]). The Biorepository team can consult further on the suggested process. Investigators can schedule a consult by contacting the SRC.

Discarded clinical samples

The following variables are paired with each discarded clinical sample in the Biorepository:

  • Date of sample collection
  • Type of sample
  • Patient’s status (+ or -)
  • Date of patient’s first positive SARS-CoV-2 test
  • Day of illness at time of sample collection (i.e., days form first positive test to sample collection date)
  • Age
  • Sex

Many investigators will require clinical data beyond the list of variables above, for instance to determine samples of interest (e.g., eligibility criteria) or stratify data for analyses. This may require access to PHI (see more below) and additional manual chart review or collaboration with the CDW. Before submitting a request for discarded clinical samples, investigators are encouraged to consult with the Biorepository team to discuss data needs. If the investigator anticipates needing data beyond the variables listed above, the CDW team will be invited to the consultation. Investigators can schedule a consult by contacting the SRC.

Protected Health Information (PHI)

All Biorepository samples and data are released to investigators coded with unique IDs. However, if an investigator wishes to connect a sample with clinical data beyond that which is provided, they must obtain institutional review board (IRB) approval to obtain these data and link them to Biorepository samples with PHI. Additional clinical information may be obtained either through the BMC Clinical Data Warehouse (CDW) or through manual chart abstraction. For example, if an investigator wishes to obtain discarded clinical samples from patients with severe COVID disease, they must obtain IRB approval to identify these patients and use PHI to link their medical record with the Biorepository. The investigator would provide the MRN and/or sample accession number(s) to the Biorepository to identify the samples within the inventory.

Similarly, but conversely, an investigator may wish to obtain a certain type of sample from the Biorepository then link these samples to the EMR. The investigator must obtain IRB approval to use this method. An investigator wishing to link samples to PHI must provide an attestation to the Biorepository that they have received IRB approval to do so. 

BMC Clinical Data Warehouse (CDW) Application 

The CDW Data Request Form can be found here.